Santhera Pharmaceuticals Holding AG’s obtaining a world-wide exclusive license for a product candidate for the treatment of cystic fibrosis from Polyphor

Paolo Bossi

Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had obtained a world-wide exclusive license from Swiss pharmaceutical company Polyphor AG to develop and commercialize a…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Paolo Bossi

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here